Abstract
Interferons alpha and beta have been reported to cause tumor regression in a small proportion of patients with recurrent glioma. Eflornithine, an irreversible inhibitor of ornithine decarboxylase, reduces cellular polyamine levels and has also been reported to cause tumor regression in patients with recurrent anaplastic astrocytoma and glioblastoma multiforme. In vitro evidence suggests that interferon and eflornithine are synergistic. In this phase II trial, we investigated the combination of recombinant alpha interferon (36 × 106 units/m2 subcutaneously days 3 to 7) and eflornithine (2.25 g/m2 QID PO days 1 to 7) repeated every 28 days. All 29 patients entered in the study were evaluable for toxicity and efficacy. Toxicity consisted primarily of fever, chills, myalgia, weakness and fatigue as well as cortical dysfunction including somnolence, confusion, and exacerbation of underlying neurologic deficits. One patient died from cerebral herniation attributable to interferon. None of the patients experienced objective tumor regression. Seven patients (24%) were stable for more than six months, but the disease stability could also be explained by indolent underlying disease or inability to distinguish recurrent tumor from delayed radiation effects. Intermittent high-dose recombinant interferon alpha plus eflornithine demonstrated no definite antitumor effects in this trial.
Similar content being viewed by others
References
Duffy DE, Santner TJ: Confidence intervals for a binomial parameter based on multistage tests. Biometrics 43: 81–93, 1987
Ganju V, Edmonson JH, Buckner JC: Phase I study of combined alpha interferon, alpha difluoromethylornithine (DFMO), and doxorubicin in advanced malignancy. Invest New Drugs 12: 25–27, 1994
Hiesiger EM, Fowler J, Brodie JD, Logan L, MacGregor R, Christman D, Flamm ET, Wolf AP: Imaging of human brain tumors by positron emission tomography (PET) using [1-11C] putrescine (11C-PU) and [1-11C]-2-deoxyglucose [11C-2DG) (abstract). Proc Am Assoc Cancer Res 27: 155, 1986
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assn 53: 457–481, 1958
Kovach JS, Svingen PA: Enhancement of the antiproliferative activity of human interferon by polyamine depletion. Cancer Treat Rep 69: 97–103, 1985
Levin VA, Prados MD, Yung WK, Gleason MJ, Ictech S, Malec M: Treatment of recurrent gliomas wit eflornithine. JNCI 84: 1432–1437, 1992
Mahaley MS Jr, Urso MB, Whaley RA, Blue M, Williams TE, Guaspari A, Selker RG: Immunobiology of primary intracranial tumors. Part 10: therapeutic efficacy of interferon in the treatment of recurrent gliomas. J Neurosurg 63: 719–725, 1985
Marton LJ, Pegg AE: Polyamines as targets for theurapeutic intervention. Ann Rev Pharmacol Toxicol 35: 55–91, 1995
McCann PP, Pegg AE: Ornithine decarboxylase as an enzyme target for therapy. Pharmacol Therap 54: 195–215, 1992
Seidenfeld J, Gray JW, Marton LF: Depletion of 9L rat brain tumor cell polyamine content by treatment with D, L-alphadifluoromethylornithine inhibits proliferation and the G to S transition. Exp Cell Res 131: 209–216, 1981
Yung WK, Prados M, Levin VA, Fetell MR, Bennett J, Mahaley MS, Salcman M, Etcubanas E: Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J Clin Oncol 9: 1945–1949, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Buckner, J.C., Burch, P.A., Cascino, T.L. et al. Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma. J Neurooncol 36, 65–70 (1998). https://doi.org/10.1023/A:1005870329601
Issue Date:
DOI: https://doi.org/10.1023/A:1005870329601